MARKET

SCNLD

SCNLD

Scancell Holdings Plc London
OTCPK
0.141
NaN%
Closed 09:30 10/22 EDT
OPEN
--
PREV CLOSE
1.410
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
3.134
52 WEEK LOW
0.119
MARKET CAP
17.09M
P/E (TTM)
-6.0000
1D
5D
1M
3M
1Y
5Y
1D
Scancell clears share consolidation as it readies AIM trading and deal push
TipRanks · 2d ago
Scancell Issues Shares Ahead of Consolidation and Publishes 2026 Annual Report
TipRanks · 10/15 06:08
Scancell Bolsters Cancer Immunotherapy Push With Nasdaq Move and $75m Funding
TipRanks · 10/09 06:11
Scancell Secures Up to US$25m BlackRock Debt to Drive iSCIB1+ Phase 3
TipRanks · 09/24 06:15
Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development
Barchart · 09/24 00:00
Scancell to Highlight Late-Stage Cancer Immunotherapy and U.S. Deal Plans at Wainwright Conference
TipRanks · 09/03 13:03
Scancell Wins UK Green Light for Global Phase 3 Melanoma Trial of iSCIB1+
TipRanks · 08/19 06:09
Scancell Extends CSO Share Option Exercise Period
TipRanks · 07/31 06:08
More
About SCNLD
Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is engaged in studying the human adaptive immune system, to generate medicines to treat unmet needs in cancer. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2, SC129, SC134, SC2811, SC27, and others. Modi-1 is the first therapeutic vaccine candidate from the Company’s Moditope platform, which targets citrullinated peptides from two different proteins which have been combined to reduce the possibility of tumor escape and have each been conjugated to a toll-like receptor (TLR) 1/2 agonist, which acts as an adjuvant. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company’s Moditope platform and has the potential to address different cancer indications to Modi-1.

Webull offers Scancell Holdings Plc stock information, including OTCPK: SCNLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCNLD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SCNLD stock methods without spending real money on the virtual paper trading platform.